FDA grants SpringWorks nirogacestat breakthrough treatment

hard fibroids are a rare soft tissue tumor that is deactivation and can lead to disfigurementIt can quickly invade the surroundinghealthy(http://tissue, causing severe pain, internal bleeding, limited movement range, and even deathThe U.SFDA(http://granted the company the nirogacestat breakthrough therapy to treat recurrent or refractive, untreatable, hard fibroids or deep fibroids, springWorks(http://) announced todayAbout Nirogacestat
Nirogacestat is an oral-specific gamma-secretion enzyme small molecule inhibitorNirogacestat is an oral-specific gamma-secretion enzyme small molecule inhibitorThe gamma-secretion enzyme is capable of cutting a variety of transmembrane protein complexes, including the Notch proteinThe Notch protein is thought to activate the signaling pathwaythat that causes the growth of hard fibroids 　　In addition to treating hard fibroids, SpringWorks has entered into a research and development agreement with GlaxoSmithKline (GSK) to test the effectiveness of niroestat in combination with other MM therapies in patients with multiple myeloma (MM) 　　This breakthrough therapy was determined to be based on nirogascestat's performance in the treatment of phase1 and 2 clinical trial setrial
sesame (http:// in 24 patients with hard fibroids 　　In these studies, the nirogacestat treatment showed a 100% disease control rate, and the median progression of the patient soutcomes was not reached at the time the trial data was published due to the lack of progression in the patient's disease